Borazan Ersin, Konduk Buğra Tolga
Department of General Surgery, Gaziantep University Faculty of Medicine, Gaziantep-Turkey.
Department of Gastroenterology, Gaziantep University Faculty of Medicine, Gaziantep-Turkey.
Ulus Travma Acil Cerrahi Derg. 2020 Sep;26(5):746-753. doi: 10.14744/tjtes.2020.61289.
Although ERCP (Endoscopic retrograde cholangiopancreatography) perforation is a rare complication, it results in high morbidity and mortality. In this study, clinical evaluation was performed concerning the incidence, clinical data and time of diagnosis for ERCP perforations that were either surgically or medically treated. To reduce the ERCP perforations and related mortality, in this study, we aimed to reveal the clinical features and compare them with the literature.
In this clinical retrospective study, 51 perforations were detected in 8676 ERCP procedures performed in the past eight years in our hospital. We compared the two groups: early diagnosed patients [Group 1: n=40] and the delayed diagnosed patients [Group 2: n=11] concerning primary diagnosis, blood and biochemical tests before ERCP, perforation type, treatment method, clinical features, length of stay, and mortality. These groups were compared concerning stent placement, papillotomy choledochal dilatation and the number of ERCP procedures.
The ERCP perforation rate in our hospital was 0.59%. The majority of patients who underwent ERCP procedures was due to the choledocholithiasis and periampullary tumors. The mean age was 62.78±17.13 (24-89 years old) and 56.9% of the patients (n=29) were women. Stapfer type II perforations (49%) were the most common type of perforation. However, 62.5% of the total mortality occurred in patients with type I perforation. The overall mortality rate was 13.72% (n=7). The duration of hospitalization (13.38±10.09 days) was higher in the patients who were treated surgically (n=24). Choledochal stents were utilized mostly in the medically treated patients (74.1%) (p=0.039). The patients in Group 1 were detected visually by the operator during the ERCP by leakage of contrast substance (13/40) or by abdominal tomography due to clinical suspicion. Patients in Group 2 had higher pre-ERCP leukocyte levels (p=0.044). The urgent surgery requirement in Group 2 was 72.7%, while the mortality rate was 36.4%. Significant mortality difference was observed between the early and late detection of perforations, indicating a higher rate in Group 2 (p=0.014).
In the patients who were diagnosed early, fewer surgical interventions were required, except for the type I perforations. Type II perforations can often be safely treated non-surgically if there are no signs of acute abdomen and sepsis. Early diagnosis and treatment significantly reduce ERCP-related mortality.
尽管内镜逆行胰胆管造影术(ERCP)穿孔是一种罕见的并发症,但它会导致高发病率和死亡率。在本研究中,我们对接受手术或药物治疗的ERCP穿孔的发生率、临床数据及诊断时间进行了临床评估。为减少ERCP穿孔及相关死亡率,本研究旨在揭示其临床特征并与文献进行比较。
在这项临床回顾性研究中,我们在我院过去八年进行的8676例ERCP手术中检测到51例穿孔。我们比较了两组:早期诊断患者[第1组:n = 40]和延迟诊断患者[第2组:n = 11],比较内容包括初步诊断、ERCP术前血液和生化检查、穿孔类型、治疗方法、临床特征、住院时间及死亡率。还比较了两组在支架置入、乳头切开胆管扩张及ERCP手术次数方面的情况。
我院的ERCP穿孔率为0.59%。接受ERCP手术的大多数患者是由于胆总管结石和壶腹周围肿瘤。平均年龄为62.78±17.13岁(24 - 89岁),56.9%的患者(n = 29)为女性。Stapfer II型穿孔(49%)是最常见的穿孔类型。然而,I型穿孔患者的总死亡率占62.5%。总死亡率为13.72%(n = 7)。手术治疗患者(n = 24)的住院时间(13.38±10.09天)更长。胆总管支架大多用于药物治疗的患者(74.1%)(p = 0.039)。第1组患者在ERCP过程中由操作人员通过造影剂渗漏(13/40)肉眼检测到,或因临床怀疑通过腹部断层扫描检测到。第2组患者ERCP术前白细胞水平较高(p = 0.044)。第2组的紧急手术需求为72.7%,而死亡率为36.4%。穿孔的早期和晚期检测之间观察到显著的死亡率差异,表明第2组的死亡率更高(p = 0.014)。
在早期诊断的患者中,除I型穿孔外,所需的手术干预较少。如果没有急腹症和脓毒症的迹象,II型穿孔通常可以安全地进行非手术治疗。早期诊断和治疗可显著降低ERCP相关的死亡率。